Therapeutic antibody optimization is time and resource intensive, largely because it requires 11 low-throughput screening (10 3 variants) of full-length IgG in mammalian cells, typically resulting 12 in only a few optimized leads. Here, we use deep learning to interrogate and predict antigen-13 specificity from a massive diversity of antibody sequence space. Using a mammalian display 14 platform and the therapeutic antibody trastuzumab, rationally designed site-directed 15 mutagenesis libraries are introduced by CRISPR/Cas9-mediated homology-directed repair 16 (HDR). Screening and deep sequencing of relatively small libraries (10 4 ) produced high quality 17 data capable of training deep neural networks that accurately predict antigen-binding based on 18 antibody sequence (~85% precision). Deep learning is then used to predict millions of antigen 19 binders from an in silico library of ~10 8 variants. Finally, these variants are subjected to multiple 20 developability filters, resulting in tens of thousands of optimized lead candidates, which when 21 a small subset of 30 are expressed, all 30 are antigen-specific. With its scalability and capacity 22 to interrogate a vast protein sequence space, deep learning offers great potential for antibody 23 engineering and optimization.
INTRODUCTION
In antibody drug discovery, the 'target-to-hit' stage is a well-established process, as screening 27 hybridomas, phage or yeast display libraries typically result in a number of potential lead candidates. 28 However, the time and costs associated with lead candidate optimization often take up the majority of 29 the preclinical discovery and development cycle 1 . This is largely due to the fact that lead optimization 30 of antibody molecules consists of addressing multiple parameters in parallel, including expression level, 31 viscosity, pharmacokinetics, solubility, and immunogenicity 2,3 . Once a lead candidate is discovered, 32 additional engineering is often required; phage and yeast display offer a powerful method for high- 33 throughput screening of large mutagenesis libraries (>10 9 ), however they are primarily only used for 34 increasing affinity or specificity to the target antigen 4 . The fact that nearly all therapeutic antibodies 35 require expression in mammalian cells as full-length IgG means that the remaining development and 36 optimization steps must occur in this context. Since mammalian cells lack the capability to stably 37 replicate plasmids, this last stage of development is done at very low-throughput, as elaborate cloning, 38 transfection and purification strategies must be implemented to screen libraries in the max range of 10 3 , 39 meaning only minor changes (e.g., point mutations) are screened 5 . Interrogating such a small fraction 1 of protein sequence space also implies that addressing one development issue will frequently cause 41 rise of another or even diminish antigen binding altogether, making multi-parameter optimization very 42 challenging. 43 Machine learning applied to biological sequence data offers a powerful approach to construct models 44 capable of making predictions of genotype-phenotype relationships 6, 7 . This is due to the capability of 45 models to extrapolate complex relationships between sequence and function. One of the principle 46 challenges in constructing accurate machine learning models is the collection of appropriate high- 47 quality training data. Directed evolution platforms are well-suited for this as they rely on the linking of 48 biological sequence data (DNA, RNA, protein) to a phenotypic output 8 . In fact, it has long been proposed 49 to use machine learning models trained on data generated by mutagenesis libraries as a means to 50 guide protein engineering 9, 10 . Recently, Gaussian processes, a Bayesian learning model, was used to 51 engineer cytochrome enzymes, enabling navigation through a vast protein sequence space to discover 52 highly thermostable variants 11 . Similarly, the design and screening of a structure-guided library of 53 channel rhodopsin membrane proteins was used to train Gaussian process and regression models, 54 which were able to accurately predict variants that could express and localize on mammalian cell 55 membranes 12 . 56 In recent years, access to deep sequencing and parallel computing has enabled the construction of 57 deep learning models capable of predicting molecular phenotype from sequence data 13, 14 . For example, 58 deep learning has been used to learn the sequence specificities of RNA-and DNA-binding proteins 15 , 59 regulatory grammar of protein expression in yeast 16 , and HLA-neoantigen presentation on tumor cells 17 . 60 In most cases deep (artificial) neural networks represent the class of algorithm utilized. While the 61 complexity of neural networks has changed drastically since their conception, the fundamental concept 62 remains the same: mimicking the connections of biological neurons to learn complex relationships 63 between variables 18 . As an extension of a single-layer neural network, or perceptron 19 , deep learning 64 incorporates multiple hidden layers to deconvolute relationships buried in large, high-dimensional data 65 sets, such as the millions of reads gathered from a single deep sequencing experiment. Well trained 66 models can then be used to make predictions on completely unseen and novel variants. This application 67 of model extrapolation lends itself perfectly to protein engineering because it provides a way to 68 interrogate a much larger sequence space than what is physically possible. For example, even for a 69 short stretch of just 10 amino acids, the combinatorial sequence diversity explodes to 10 13 , a size which 70 is nearly impossible to interrogate experimentally. 71 Here, we leverage the power of deep learning to perform multi-parameter optimization of therapeutic 72 antibodies (full-length IgG) directly in mammalian cells (Figure 1 ). Starting with a mammalian display 73 cell line 20 expressing the therapeutic antibody trastuzumab (Herceptin), we use CRISPR-Cas9-74 mediated homology-directed repair (HDR) to introduce site-directed mutagenesis libraries in the 75 variable heavy chain complementarity determining region 3 (CDRH3) 21 . In order to generate information 76 rich training data, single-site deep mutational scanning (DMS) is first performed 22 , which is then used 77 to guide the design of combinatorial mutagenesis libraries. An experimental (physical) library size of 5 78 x 10 4 variants was then screened for specificity to the antigen HER2. All binding and non-binding variant 2 sequences were then used to train recurrent and convolutional deep neural networks, which when fully-80 trained and optimized were able with high accuracy and precision to predict antigen-specificity based 81 on antibody sequence. Neural networks are then used to predict antigen-specificity on a subset of 82 sequence variants from the DMS-based combinatorial mutagenesis library (~10 8 sequences), resulting 83 in >3.0 x 10 6 variants predicted to have a high probability of being antigen-specific. These variants are 84 then subjected to several sequence-based in silico filtering steps to optimize for developability 85 parameters such as viscosity, solubility and immunogenicity, resulting in over 40,000 optimized 86 antibody sequence variants. Finally, a random selection of variants were recombinantly expressed and 87 tested, resulting in 30 out of 30 showing antigen-specific binding. 88 89
RESULTS

90
Deep mutational scanning determines antigen-specific sequence landscapes and guides 91 rational antibody library design 92 As the amino acid sequence of an antibody's CDRH3 is a key determinant of antigen specificity, we 93 performed DMS on this region to resolve the specificity determining residues. To start, a hybridoma 94 cell-line was used that expressed a trastuzumab variant that could not bind HER2 antigen (mutated 3 CDRH3 sequence) ( Supplementary Fig. 1 ). Libraries were generated by CRISPR-Cas9-mediated 96 homology-directed mutagenesis (HDM) 21 , which utilized guide RNA (gRNA) for Cas9 targeting of 97 CDRH3 and a pool of homology templates in the form of single-stranded oligonucleotides (ssODNs) 98 containing NNK degenerate codons at single-sites tiled across CDRH3 (Figure 2a , Supplementary Fig.   99 2). Libraries were then screened by fluorescence activated cell sorting (FACS), and populations 100 expressing surface IgG which either were binding or not binding to antigen were isolated and subjected 101 to deep sequencing (Illumina MiSeq) ( Supplementary Table 1 ). Deep sequencing data was then used 102 to calculate enrichment scores of the 10 positions investigated, which revealed six positions that were 103 sufficiently amenable to a wide-range of mutations and an additional three positions that were 104 marginally accepting to defined mutations ( Figure 2b ). Although residues 102D, 103G, 104F, and 105Y 105 appear to be contacting amino acids of the CDRH3 loop with HER2 23,24 , 105Y is the only residue 106 completely fixed (Figure 2c ). 107 4 Heatmaps and their corresponding sequence logo plots generated by DMS were used to guide the 109 rational design of combinatorial mutagenesis libraries, which consisted of degenerate codons across 110 all positions (except 105Y) ( Supplementary Fig. 3 , Supplementary Table 6 ). Degenerate codons were 111 selected per position based on their amino acid frequencies which most closely resembled the degree 112 of enrichment found in the DMS data following 1, 2, and 3 rounds of antigen-specific enrichment 113 ( Supplementary Fig. 2, Equation 2 ). This combinatorial library possesses a theoretical protein sequence 114 space of 7.17 x 10 8 , far greater than the single-site DMS library diversity of 200. Libraries containing 115 CDRH3 variants were again generated in hybridoma cells through CRISPR-Cas9-mediated HDM in the 116 same non-binding trastuzumab clone described previously (Figure 3a ). Antigen binding cells were 117 isolated by two rounds of enrichment by FACS (Figure 3b, Supplementary Fig. 3 ) and the binding/non-118 binding populations were subjected to deep sequencing. Sequencing data identified 11,300 and 27,539 119 unique binders and non-binders, respectively (Supplementary Table 2 ). These sequence variants 120 represented only a miniscule 0.0054% of the theoretical protein sequence space of the combinatorial 121 mutagenesis library. Amino acid usage per position was comparatively similar between antigen binding 122 and non-binding populations (Figure 3c ), thus making it difficult to develop any sort of heuristic rules or 123 observable patterns to identify binding sequences.
124
Training deep neural networks to classify antigen-specificity based on antibody sequence 126 After having compiled deep sequencing data on binding and non-binding CDRH3 variants, we set out 127 to develop and train deep learning models capable of predicting specificity towards the target antigen 128 HER2. Amino acid sequences were converted to an input matrix by one-hot encoding, an approach 129 where each column of the matrix represents a specific residue and each row corresponds to the position 130 in the sequence, thus a 10 amino acid CDRH3 sequence as here results in a 10 x 20 matrix. Each row 131 will contain a single '1' in the column corresponding to the residue at that position, whereby all other 132 columns/rows receive a '0'. We utilized long short-term memory recurrent neural networks (LSTM-RNN) 133 and convolutional neural networks (CNN), which represent two of the main classes of deep learning 134 models used for biological sequence data 14 . LSTM-RNNs and CNNs both stem from standard neural 135 networks, where information is passed along neurons that contain learnable weights and biases, 136 however, there are fundamental differences in how the information is processed. LSTM-RNN layers 137 contain loops, enabling information to be retained from one step to the next, allowing models to 138 efficiently correlate a sequential order with a given output; CNNs, on the other hand, apply learnable 139 filters to the input data, allowing it to efficiently recognize spatial dependencies associated with a given predictions on the unseen testing data sets (Figure 4b, d ). Based on conventional approaches to training 151 classification models, the data set was adjusted to allow for a 50/50 split of binders and non-binders 152 during training. Under these training conditions, the LSTM-RNN and CNN were both able to accurately 153 classify unseen test data (ROC curve AUC: 0.9 ± 0.0, average precision: 0.9 ± 0.0, Supplementary Fig.   154 6). 155 Next, we used the trained LSTM-RNN and CNN models to classify a random sample of 1 x 10 5 156 sequences from the potential sequence space. We observed, however, an unexpectedly high 157 occurrence of positive classifications (25,318 ± 1,643 sequences or 25.3 ± 1.6%, Supplementary Table   158 3b). With the knowledge that the physiological frequency of binders should be approximately 10-15%, 159 we sought to adjust the classification split of the training data with the hypothesis that models were 160 being subject to some unknown classification bias. Additional models were then trained on classification 161 splits of both 20/80, and 10/90 binders/non-binders, as well as a classification split with all available 162 data (approximately 30/70 binders/non-binders). Unbalancing the sequence classification led to a 163 significant reduction in the percentage of sequences classified as binders, but also led to a reduction in 164 the model performance on the unseen test data ( Supplementary Fig. 4-7 , Supplementary Tables 3a,  6 b). Through our analysis, we concluded that the optimal data set for training the models was the set 166 inclusive of all known CDRH3 sequences for the following reasons: 1) the percentage of sequences 167 predicted as binders reflects this physiological frequency, 2) this data set maximizes the information 168 the model sees, and 3) model performance on both test data sets. Final model architecture, parameters, 169 and evaluation are shown in Figure 4 . As a final measure of model validation, neural networks were 170 trained with a data set containing randomly shuffled binding and non-binding class labels. Model 171 performance of these networks revealed indiscriminate sequence classification on unseen test data 172 ( Supplementary Fig. 8 to classify all 7.2 x 10 7 sequence variants as either antigen binders or non-binders based on a probability 180 score (P), resulting in a prediction of 8.55 x 10 6 (LSTM-RNN) and 9.52 x 10 6 (CNN) potential binders 181 (P > 0.50). This represented a reasonable fraction (11-13%) of antigen-specific variants based on 182 experimental screening (Figure 3b ). To increase confidence, we increased the prediction threshold for 183 binder classification to P > 0.75 and took the consensus binders between the LSTM- RNN and CNN. 184 This reduced the antigen-specific sequence space down to 3.0 x 10 6 variants. 185 Next, we characterized the 3.0 x 10 6 predicted antigen-specific sequences on a number of parameters. 186 As a first metric, we investigated their sequence similarity to the original trastuzumab sequence by 187 calculating the Levenshtein distance (LD). The majority of sequences showed an edit distance of LD > 188 4 ( Figure 5a ). The first step in filtering was to calculate the net charge and hydrophobicity index in order 189 to estimate the molecule's viscosity and clearance 2 . According to Sharma et al., viscosity decreases 190 with increasing variable fragment (Fv) net charge and increasing Fv charge symmetry parameter 191 (FvCSP); however, the optimal Fv net charge in terms of drug clearance is between 0 and 6.2 with a 192 CDRL1+CDRL3+CDRH3 hydrophobicity index sum < 4.0. Based on the wide range of values for these 193 parameters in the 3.0 x 10 6 predicted variants (Figure 5b , c), we filtered any sequences out that had a 194 Fv net charge > 4.2 and a CDRH3 hydrophobicity index > 4.0, which further reduced the sequence 195 space down to 1.93 x 10 6 variants. We next padded the CDRH3 sequences with 10 amino acids on the 196 5' and 3' ends and then ran these sequences through CamSol, a protein solubility predictor developed 197 by Sormanni et al. 25 , which estimates and ranks sequence variants based on their theoretical solubility. 198 The remaining variants produced a wide-range of protein solubility scores ( Figure 5d ) and sequences 199 with a score < 0.2 were filtered out, leaving 2.36 x 10 5 candidates for further analysis. As a last step in 200 our in silico screening process, we aimed at reducing immunogenicity by predicting the peptide binding and those with an average % Rank < 70 were also filtered out (Figure 5f ). Based on these criteria, there 210 were 40,588 multi-parameter optimized variants ( Figure 5g ).
212
Optimal antibody sequences are recombinantly expressed and antigen-specific 213 To validate the precision of our fully trained LSTM-RNN and CNN models, we randomly selected a 214 subset of 30 CDRH3 sequences predicted to be antigen-specific and optimized across the multiple 215 developability parameters. To further demonstrate the capacity of deep learning to identify novel 216 sequence variants, we also added the criteria that the selected variants must have a minimum LD of 5 217 from the original CDRH3 sequence of trastuzumab, resulting in a library of 32,725 sequences to select 218 from. CRISPR-Cas9-mediated HDR was used to generate mammalian display cell lines expressing the 219 30 different sequence variants. Flow cytometry was performed and revealed that 30 of the 30 variants 10 (100%) were antigen-specific ( Figure 6a ). Further analysis was performed on 14 of the antigen-binding 221 variants to more precisely quantify the binding kinetics via biolayer interferometry (BLI, FortéBio Octet 222 RED96e) ( Figure 6b ). The original trastuzumab sequence was measured to have an affinity towards 223 HER2 of 4.0 x 10 -10 M (equilibrium dissociation constant, KD); and although the majority of variants 224 tested had a slight decrease in affinity, 71% (10/14) were still in the single-digit nanomolar range, 21% 225 (3/14) remained sub-nanomolar, and one variant (7%) showed a near 3-fold increase in affinity 226 compared to trastuzumab (KD = 1.4 x 10 -10 M). We also investigated any correlations between flow 227 cytometry fluorescence intensity and BLI measured affinity ( Supplementary Fig. 9 ), as well as model 228 prediction values and measured affinities ( Supplementary Fig. 10) . While there appears to be an overall 229 increasing trend between fluorescence intensity and binding affinity, there also exists outlying points 230 with low fluorescence signals, but high affinity values. Conversely, no observable trend is present when 231 comparing model prediction values to binding affinities, however, the highest affinity variants do tend to 232 have higher prediction values. Figure 6c displays the 30 tested sequence variants along with their 233 associated developability and affinity metrics.
12
DISCUSSION
236
Addressing the limitation of antibody optimization in mammalian cells, we have developed an approach 237 based on deep learning that enables us to identify antigen-specific sequences with high precision. Using 238 the clinically approved antibody trastuzumab, we performed single-site DMS followed by combinatorial 239 mutagenesis to determine the antigen-binding landscape of CDRH3. This DMS-based mutagenesis 240 strategy is crucial for attaining high quality training data that is enriched with antigen-binding variants, 241 in this case nearly 10% of our library (Figure 3b ). In contrast, if a completely randomized combinatorial 242 mutagenesis strategy was employed (i.e., NNK degenerate codons), it would be unlikely to produce 243 any significant fraction of antigen-binding variants. In the future, other approaches to mutagenesis that 244 generate enriched training data 27 , such as shotgun scanning mutagenesis 28 , binary substitution 29 and 245 recombination 30,12 may also be explored for training deep neural networks. 246 A remarkable finding in this study was that experimental screening of a library of only 5 x 10 4 variants, Figure 3c ), suggesting that neural networks are effectively capturing non-linear patterns/interactions. 254 In the current study, we selected LSTM-RNNs and CNNs as the basis of our classification models, as 255 they represent two state-of-the-art approaches in deep learning. Other machine learning approaches 256 such as k-nearest neighbors, random forests, and support vector machines are also well-suited at 257 identifying complex patterns from input data, but as data set sizes continue to grow, as is realizable 258 with biological sequence data, deep neural networks tend to outperform these classical techniques 15 . 259 Furthermore, deep generative modeling methods such as variational autoencoders may also be used 260 to explore the mutagenesis sequence space from directed evolution 31 . 261 We in silico generated approximately 7.2 x 10 7 CDRH3 variants from DMS-based combinatorial 262 diversity and used fully trained LSTM-RNN and CNN models to classify each sequence as a binder or 263 non-binder. The 7.2 x 10 7 sequence variants comprise only a subset of the potential sequence space 264 and was chosen to minimize the computational effort, however, it still represents a library size several 265 orders of magnitude greater than what is experimentally achievable in mammalian cells. We easily 266 envision extending the screening capacity through script optimization and employing parallel computing (Figure 3b ). With the exception of critical 270 residues determined by DMS, the majority of predicted binders were substantially distant from the 271 original trastuzumab sequence with 80% of sequences having an edit distance of at least 6 residues. 272 This high degree of sequence variability indicated the potential for a wide range of biomolecular 273 properties.
13
Once an antibody's affinity for its target antigen is within a desirable range for efficacious biological 275 modification, addressing other biomolecular properties becomes the focus of antibody development. 276 With recent advances in computational predictions 32,33 , a number of these properties, including 277 viscosity, clearance, stability 2 , specificity 34 , solubility 25 and immunogenicity 26 can be approximated from 278 sequence information alone. With the aim of selecting antibodies with improved characteristics, we 279 subjected the library of predicted binders to a number of these in silico approaches in order to provide 280 a ranking structure and filtering strategy for developability ( Figure 5 ). After implementing these methods 281 to remove variants with a high likelihood of having poor viscosity, clearance or solubility, as well as 282 those with high immunogenic potential, over 40,000 multi-parameter optimized antibody variants 283 remained. It is interesting to note that a considerable number of sequences scored even better than the 284 original trastuzumab sequence. Future work to apply more stringent or additional filters which address 285 other developability parameters (e.g. stability, specificity, humanization) could also be implemented to 286 further reduce the sequence space down to highly developable therapeutic candidates. For instance, 287 previous studies have investigated the likeness of therapeutic antibodies to the human antibody 288 repertoire 35 . 289 Lastly, to experimentally validate the precision of neural networks to predict antigen specificity, we 290 randomly selected and expressed 30 variants from the library of optimized sequences with a minimum 291 edit distance of 5 from trastuzumab. The precision of the LSTM-RNN and CNN models were each 292 estimated to be ~85% (at P > 0.75) according to predictions made on the test data sets (Figure 4b, d) . 293 By taking the consensus between models, however, we experimentally validated that all randomly 294 selected (30/30) of the antigen-predicted (and developability filtered) sequences were indeed binders, 295 and several of which were high affinity. While we anticipate false positives would be discovered by 296 increasing the sample size tested, validation of this subset strongly infers that potentially thousands of 297 optimized lead candidates maintain a binding affinity in the range of therapeutic relevance, while also 298 containing substantial sequence variability from the starting trastuzumab sequence. Future work to 299 increase the stringency of selection during screening or a more detailed investigation of correlations 300 between prediction probability and affinity could prove insightful towards retaining high target affinities. 301 We also envision this approach to enable the optimization of other functional properties of therapeutic 302 antibodies, such as pH-dependent antibody recycling 36 or affinity/avidity tuning 37,38 . Additionally, 303 extending this approach to other regions across the variable light and heavy chain genes, namely other 304 CDRs, may yield deep neural networks that are able to capture long-range, complex relationships 305 between an antibody and its target antigen. To understand these patterns in greater depth, it may also 306 prove useful to compare neural network predictions with protein structural modeling predictions 39 . were used to calculate the total theoretical sequence space of 7.17 x 10 8 . 7.2 x 10 7 sequence variants 406 were generated in silico by taking all possible combinations of the amino acids used per position in the 407 combinatorial mutagenesis library designed from the DMS data following three rounds of enrichment 408 for antigen binding variants ( Supplementary Fig. 2c, 3c) ; Alanine was also selected to be included at 409 position 103. All in silico sequences were then classified as a binder or non-binder by the trained LSTM-410 RNN and CNN models. Sequences were selected for further analysis if they were classified in both 411 models with a prediction probability (P) of more than 0.75. 412 The Fv net charge and Fv charge symmetry parameter (FvCSP) were calculated as described by Theor. Biol. 234, 187-199 (2005) . Position freq Amino Acid Figure 1 : Implementing deep learning to predict antibody target specificity (a) Generating quality data capable of training accurate models. First, deep mutational scanning assesses the impact mutations have on protein function across many different positions. These insights can then be applied to combinatorial mutagenesis strategies to guide protein library design capable of producing thousands of binding variants. (b) Sequence information for binders and nonbinders can then be used to train deep neural networks to accurately predict antigen specificity of unknown antibody variants, producing millions of predicted binders. These binders can then be subjected to any available in silico methods for predicted various developability attributes. (a) Flow cytometry profile following integration of tiled mutations by homology-directed mutagenesis. Antigen specific variants underwent 3 rounds of enrichment ( Supplementary Fig. 2) (b) Corresponding heatmap (left) following sequencing analysis of the pre-sorted (Ab+) and post-sorted (Ag+) populations ( Supplementary Table 1 ). Wild type amino acids are marked by black circles. The resulting sequence logo plot (right) generated by positively enriched mutations per position. (c) 3D protein structure of trastuzumab in complex with its target antigen, HER2 23,24 . Locations of surface exposed residues: 102D, 103G, 104F, and 105Y are given 40 .
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Herceptin CDRH3 Variant Non-specific for HER2 Position freq Amino Acid Position freq Amino Acid Flow cytometry plots resulting from transfection of a rationally designed library. Two rounds of enrichment were performed to produce a library of antigen specific variants. Deep sequencing was performed on the library (Ab+), nonbinding variants (Ag-), and binding variants after 1 and 2 rounds of enrichment (Ag+1, Ag+2) ( Supplementary Fig. 3 , Supplementary Table 2 ). 
